Metabolism of oxycodone in human hepatocytes from different age groups and prediction of hepatic plasma clearance

Frontiers in Pharmacology

Volumn 3 JAN, Issue , 2012, Pages

  Korjamo, Timo ^a,f   Tolonen, Ari ^b   Ranta, Veli Pekka ^c   Turpeinen, Miia ^d   Kokki, Hannu ^e  

^a Novamass Ltd   (Finland)

^b Admescope Ltd   (Finland)

^c UNIVERSITY OF EASTERN FINLAND   (Finland)

^d UNIVERSITY OF OULU   (Finland)

^e KUOPIO UNIVERSITY HOSPITAL   (Finland)

^f ORION CORPORATION   (Finland)

Author keywords

Cytochrome P450; Drug metabolism; Hepatocytes; In vitro; Oxycodone; Pediatric model

Indexed keywords

KETOCONAZOLE; NOROXYCODONE; OXYCODONE; UNCLASSIFIED DRUG;

ARTICLE; CHILD; CONCENTRATION RESPONSE; CORRELATION ANALYSIS; CRYOPRESERVATION; DRUG METABOLISM; FEMALE; GROUPS BY AGE; HUMAN; HUMAN CELL; IN VITRO STUDY; INFANT; LIQUID CHROMATOGRAPHY; LIVER CELL; MALE; MASS SPECTROMETRY; METABOLITE; PLASMA CLEARANCE; PREDICTION; PRESCHOOL CHILD;

EID: 84860190689     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2011.00087     Document Type: Article

References (38)

1. Alcorn, J., and McNamara, P. J. (2002). Ontogeny of hepatic and renal systemic clear- ance pathways in infants: part II. Clin. Pharmacokinet. 41, 1077-1094.
2. Barter, Z. E., Bayliss, M. K., Beaune, P. H., Boobis, A. R., Carlile, D. J., Edwards, R. J., Houston, J. B., Lake, B. G., Lipscomb, J. C., Pelkonen, O. R., Tucker, G. T., and Rostami- Hodjegan, A. (2007). Scaling factors for the extrapolation of in vivo meta- bolic drug clearance from in vitro data: reaching a consensus on val- ues of human microsomal pro- tein and hepatocellularity per gram of liver. Curr.DrugMetab.8, 33-45.
3. Boström, E., Simonsson, U. S., and Hammarlund-Udenaes, M. (2006). In vivo blood-brain barrier trans- port of oxycodone in the rat: indications for active influx and implications for pharmacoki- netics/pharmacodynamics. Drug Metab. Dispos. 34, 1624-1631.
4. Brown, H. S., Griffin, M., and Houston, J. B. (2007). Evaluation of cryop- reserved human hepatocytes as an alternative in vitro system to micro- somes for the prediction of meta- bolic clearance. Drug Metab. Dispos. 35, 293-301.
5. Chiba, M., Ishii, Y., and Sugiyama, Y. (2009). Prediction of hepatic clear- ance in human from in vitro data for successful drug development. AAPS J. 11, 262-276.
6. DuBois, D., and DuBois, E. F. (1916). A formula to estimate the approximate surface area if height and weight be known. Arch. Intern. Med. 17, 863-871.
7. Edginton, A. N., Schmitt, W., Voith, B., and Willmann, S. (2006). A mech- anistic approach for the scaling of clearance in children. Clin. Pharma- cokinet. 45, 683-704.
8. El-Tahtawy, A., Kokki, H., and Reiden- berg, B. E. (2006). Population phar- macokinetics of oxycodone in chil- dren 6 months to 7 years old. J. Clin. Pharmacol. 46, 433-442.
9. Falk, E. (1917). Eukodal, ein neues narkotikum. Munch. Med. Wochen- schr. 20, 381-384.
10. FDA Guidance for Industry. (1998). General Considerations for Pediatric Pharmacokinetic Studies for Drugs and Biological Products. Rockville: Food and Drug Administration.
11. Foster, J. A., Houston, J. B., and Hal- lifax, D. (2011). Comparison of intrinsic clearances in human liver microsomes and suspended hepa- tocytes from the same donor liv- ers: clearance-dependent relation- ship and implications for prediction of in vivo clearance. Xenobiotica 41, 124-136.
12. Hallifax, D., and Houston, J. B. (2009). Methodological uncertainty in quantitative prediction of human hepatic clearance from in vitro experimental systems. Curr. Drug Metab. 10, 307-321.
13. Hassan, H. E., Myers, A. L., Lee, I. J., Coop, A., and Eddington, N. D. (2007). Oxycodone induces overexpression of P-glycoprotein (ABCB1) and affects paclitaxel's tis- sue distribution in Sprague Dawley rats. J. Pharm. Sci. 96, 2494-2506.
14. Haycock, G. B., Schwartz, G. J., and Wisotsky, D. H. (1978). Geometric method for measuring body surface area: a height-weight formula vali- dated in infants,children,and adults. J. Pediatr. 93, 62-66.
15. Heiskanen, T., Olkkola, K. T., and Kalso, E. (1998). Effects of block- ing CYP2D6 on the pharmacokinet- ics and pharmacodynamics of oxy- codone. Clin. Pharmacol. Ther. 64, 603-611.
16. International Narcotics Control Board. (2010). Narcotic Drugs: Estimated World Requirements for 2010; Sta- tistics for 2008. New York: United Nations.
17. Johnson, T. N., Rostami-Hodjegan, A., and Tucker, G. T. (2006). Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. Clin. Pharma- cokinet. 45, 931-956.
18. Johnson, T. N., Tucker, G. T., Tan- ner, M. S., and Rostami-Hodjegan, A. (2005). Changes in liver vol- ume from birth to adulthood: a meta-analysis. Liver Transpl. 11, 1481-1493.
19. Kenworthy, K. E., Clarke, S. E.,Andrews, J., and Houston, J. B. (2001). Mul- tisite kinetic models for CYP3A4: simultaneous activation and inhibi- tion of diazepam and testosterone metabolism. Drug Metab. Dispos. 29, 1644-1651.
20. Kirvelä, M., Lindgren, L., Seppälä, T., and Olkkola, K. T. (1996). The phar- macokinetics of oxycodone in ure- mic patients undergoing renal trans- plantation. J. Clin. Anesth. 8, 13-18.
21. Kokki, H., Rasanen, I., Laisalmi, M., Lehtola, S., Ranta, V. P., Vanamo, K., and Ojanperä, I. (2006). Compari- son of oxycodone pharmacokinetics after buccal and sublingual admin- istration in children. Clin. Pharma- cokinet. 45, 745-754.
22. Kokki, H., Rasanen, I., Reinikainen, M., Suhonen, P., Vanamo, K., and Ojan- perä, I. (2004). Pharmacokinetics of oxycodone after intravenous, buccal, intramuscular and gastric adminis- tration in children. Clin. Pharma- cokinet. 43, 613-622.
23. Kuczmarski, R. J., Ogden, C. L., and Guo, S. S., Grummer-Strawn, L. M., Flegal,K. M.,Mei,Z.,Wei,R.,Curtin, L. R., Roche, A. F., and Johnson, C. L. (2002). 2000 CDC growth charts for the United States: methods and development. Vital Health Stat. 11, 1-190.
24. Lalovic, B., Kharasch, E., Hoffer, C., Risler, L., Liu-Chen, L. Y., and Shen, D. D. (2006). Pharmacoki- netics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites. Clin. Pharmacol. Ther. 79, 461-479.
25. Lalovic, B., Phillips, B., Risler, L. L., Howald, W., and Shen, D. D. (2004). Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. Drug Metab. Dispos. 32, 447-454.
26. Lemberg, K. K., Heiskanen, T. E., Neu- vonen, M., Kontinen, V. K., Neuvo- nen,P. J.,Dahl,M. L.,and Kalso,E. A. (2010). Does co-administration of paroxetine change oxycodone anal- gesia: an interaction study in chronic pain patients. Scand. J. Pain 1,24-33.
27. Leow, K. P., Smith, M. T., Williams, B., and Cramond, T. (1992). Single- dose and steady-state pharmacoki- netics and pharmacodynamics of oxycodone in patients with cancer. Clin. Pharmacol. Ther. 52, 487-495.
28. Leow, K. P., Wright, A. W., Cramond, T., and Smith, M. T. (1993). Determi- nation of the serum protein binding of oxycodone and morphine using ultrafiltration. Ther. Drug Monit. 15, 440-447.
29. Okura, T., Hattori, A., Takano, Y., Sato, T., Hammarlund-Udenaes, M., Terasaki, T., and Deguchi, Y. (2008). Involvement of the pyrilamine transporter, a putative organic cation transporter, in blood-brain barrier transport of oxycodone. Drug Metab. Dispos. 36, 2005-2013.
30. Olkkola,K. T.,Hamunen,K.,Seppälä,T., and Maunuksela, E. L. (1994). Phar- macokinetics and ventilatory effects of intravenous oxycodone in postop- erative children. Br. J. Clin. Pharma- col. 38, 71-76.
31. Pokela, M. L., Anttila, E., Seppälä, T., and Olkkola, K. T. (2005). Marked variation in oxycodone pharmaco- kinetics in infants. Paediatr. Anaesth. 15, 560-565.
32. Pöyhiä, R., Olkkola, K. T., Seppälä, T., and Kalso, E. (1991). The phar- macokinetics of oxycodone after intravenous injection in adults. Br. J. Clin. Pharmacol. 32, 516-518.
33. Pöyhiä, R., and Seppälä, T. (1994). Liposolubility and protein binding of oxycodone in vitro. Pharmacol. Toxicol. 74, 23-27.
34. Pöyhiä, R., Seppälä, T., Olkkola, K. T., and Kalso, E. (1992). The phar- macokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy sub- jects. Br. J. Clin. Pharmacol. 33, 617-621.
35. Soars, M. G., Grime, K., Sproston, J. L., Webborn,P. J.,and Riley,R. J. (2007). Use of hepatocytes to assess the con- tribution of hepatic uptake to clear- anceinvivo.Drug Metab. Dispos. 35, 859-865.
36. Takala, A., Kaasalainen, V., Seppälä, T., Kalso, E., and Olkkola, K. T. (1997). Pharmacokinetic compar- ison of intravenous and intranasal administration of oxycodone. Acta Anaesthesiol. Scand. 41, 309-312.
37. Valentin, J. (ed.). (2003). Basic anatom- ical and physiological data for use in radiological protection: reference values. Ann. ICRP Publication 89, 1-265.
38. Yang, J., Jamei, M., Yeo, K. R., Rostami-Hodjegan, A., and Tucker, G. T. (2007). Misuse of the well-stirred model of hepatic drug clearance. Drug Metab. Dispos. 35, 501-502.